share_log

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3：募资说明书
美股SEC公告 ·  08/14 12:43
Moomoo AI 已提取核心信息
Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in the previously dated prospectus from April 2, 2024, with details from their quarterly report. This supplement relates to the issuance of 8,750,000 shares of common stock underlying previously issued Class E and Class F common stock purchase warrants. The shares were initially registered on a registration statement and are quoted on the OTCQB under the symbol 'PBLA.' The last reported sales price of the common stock was $0.35 per share as of August 12, 2024. The supplement, which includes the attached Quarterly Report, must be read in conjunction with the Prospectus, and in case of any inconsistency, the information in the supplement prevails. The Quarterly Report details the company's financial...Show More
Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in the previously dated prospectus from April 2, 2024, with details from their quarterly report. This supplement relates to the issuance of 8,750,000 shares of common stock underlying previously issued Class E and Class F common stock purchase warrants. The shares were initially registered on a registration statement and are quoted on the OTCQB under the symbol 'PBLA.' The last reported sales price of the common stock was $0.35 per share as of August 12, 2024. The supplement, which includes the attached Quarterly Report, must be read in conjunction with the Prospectus, and in case of any inconsistency, the information in the supplement prevails. The Quarterly Report details the company's financial status, including a net loss of $14.3 million for the six months ended June 30, 2024, and a decrease in cash from $2.578 million to $59,000. The report also mentions the risks involved in investing in the company's securities and states that the SEC has not approved or disapproved the accuracy or adequacy of the prospectus supplement or the Prospectus.
Panbela Therapeutics, Inc.于2024年8月13日提交了一份招股书补充，更新并补充了此前于2024年4月2日发布的招股书信息，其中包含来自其季度报告的详细信息。此补充文件涉及发行875万股普通股，作为先前发行的E类和F类普通股购买权证明的基础股票。这些股份最初在注册声明上进行了登记，并在OTCQb上标注为“PBLA”标的。截至2024年8月12日，普通股的最后报告销售价格为每股0.35美元。该补充文件（包括附加的季度报告）必须与招股书一起阅读，在任何冲突情况下，以补充文件中的信息为准。季度报告详细介绍了该公司的财务状况，包括截至2024年6月30日的六个月净亏损1430万美元，现金从257.8万美元降至59,000美元。报告还提到了投资该公司证券的风险，并声明SEC尚未批准或驳回招股书补充或招股书的准确性或充分性。
Panbela Therapeutics, Inc.于2024年8月13日提交了一份招股书补充，更新并补充了此前于2024年4月2日发布的招股书信息，其中包含来自其季度报告的详细信息。此补充文件涉及发行875万股普通股，作为先前发行的E类和F类普通股购买权证明的基础股票。这些股份最初在注册声明上进行了登记，并在OTCQb上标注为“PBLA”标的。截至2024年8月12日，普通股的最后报告销售价格为每股0.35美元。该补充文件（包括附加的季度报告）必须与招股书一起阅读，在任何冲突情况下，以补充文件中的信息为准。季度报告详细介绍了该公司的财务状况，包括截至2024年6月30日的六个月净亏损1430万美元，现金从257.8万美元降至59,000美元。报告还提到了投资该公司证券的风险，并声明SEC尚未批准或驳回招股书补充或招股书的准确性或充分性。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息